Phone: 866-310-7549 M-F 8AM-8PM ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax# 866-441-4190



The Novo Nordisk Minnesota State Insulin Affordability Program provides medication to qualifying applicants at no charge. If the applicant qualifies under the Minnesota State guidelines, up to a 120-day supply of the requested medication(s) or device(s) will be shipped to the patient.

Eligibility Requirements

You may qualify if:

- You are a resident of Minnesota and can provide one of the following:
 - Valid Minnesota driver's license or permit
 - Valid Minnesota identification card
 - Valid tribal identification card from a Minnesota tribe

or

- If the person who needs insulin is under the age of 18, the parent or legal guardian must provide proof of residency

- · You are not enrolled in Medicaid or low-cost health insurance sponsored by the state (Minnesota Cares)
- · You are not eligible to receive prescription drug benefits through federally funded programs, with the exception of Medicare Part D
- · You are not enrolled or eligible to receive prescription drug benefits through the Department of Veterans Affairs
- If you have private prescription drug coverage, your out-of-pocket cost for a 30-day supply of insulin is greater than \$75
- Your total household income is at or below 400% of the federal poverty level (FPL) (NeedyMeds website lists current FPL guidelines)

What to send?

- · Completed application (signed and dated by both patient and prescriber)
- Proof of income
- Copy of Minnesota driver's license or permit/identification card/Tribal card

IMPORTANT

- Sign and Date ALL applicable sections.
- Ensure ALL *required fields have been completed.
- Include ALL required supporting documentation.
- Mail/Fax completed application & copies of required income documentation.

Any missing/incomplete/illegible information may cause a delay in processing.

Questions?

Phone: 866-310-7549 Monday-Friday 8AM-8PM ET

Fax: 866-441-4190

Patients: NovoPAP.com HCPs: NovoPAPHCP.com

What to Expect Next?

- Mail/Fax completed application & required income documentation.
- · Allow 2 business days for processing.
- Enrollment decision will be sent via mail/fax to patients and healthcare providers.
- · Once approved, patients will receive a phone call to schedule delivery of medication to their home.
- Approved uninsured patients will be enrolled for 12 months. Medicare Part D patients are enrolled through the end of the calendar year and will need to reapply after October 15th for the following year.

Refills:

- · Health Care practitioners must request all refills by submitting a refill/change request form, available at www.NovoPAPHcp.com.
- This form can be submitted 80 days prior to the next refill due date.

Novo Nordisk Minnesota State Insulin Affordability Program



New Application Check one: Re-Enrollment

Asterisks indicate required field. Do not leave blank.

DAT	TENI	г сес	TION
FAI	TEIN	I SEL	TION

Patient First Name*: Last Name*:		Patient DOB*:
Patient's Street Address* (NO PO BOX):		
City:	State:	Zip:
Home Phone*:	Mobile Phone*:	
Gender: Male Female Prefer not to disclose	Email:	
Insurance		
Do you have any form of prescription drug coverage* ? If YES , please	check ALL that apply and complete info	ormation below. YES NO
Plan Name:	Member ID:	Phone#
Employer-supplied or commercial/private drug coverage Medicare Prescription Drug Coverage (include a copy of the front and back of your card) Medicare Datt B (medical back fit bat covers some prescription medications)	VA or Military Benefits Medicaid Prescription Drug Co Medicare Low Income Subsidy	-
Medicare Part B (medical benefit that covers some prescription medications) Not sure if you have Medicare Rx coverage? Medicare Part D Plan cards usual	y have "Medicare Ry" somewhere on the card	
Medicare Advantage Plans with prescription coverage also have "Medicare Rx" so	pmewhere on the card.	
Patient Authorized Representative (Optional)		
You may provide the name of an individual (i.e., spouse, sibling, child, etc.) whom you authorize Nc the Novo Nordisk PAP. Those people who you authorize to speak to Novo Nordisk PAP about you m advocacy groups as a patient-authorized representative. Novo Nordisk PAP is not affiliated with thi without permission. Patients are not required to use a third party who charges a fee to help with en	ay provide or receive your personal information as nece rd parties who charge a fee for help with enrollment. Th	ssary. Novo Nordisk does not accept paid
Yes, I would like to authorize a person to speak on my behalf. No If yes, please provide name, phone number and relationship below.	o, I do not want anyone speaking to Nov	/o Nordisk PAP on my behalf.
Authorized Representative Name:	Authorized Representative phone number:	
Family member/caregiver Other		
Patient Signature:	Date:	
To remove an authorized representative, please call Novo Nordisk PAP at 1-866-310-7549		
air Credit Reporting Act (FCRA) Consent		
You have the option to allow PAP to perform an electronic income verification to	, , ,,	
Please check here if you wish to choose this option and not send in your inco	ome documents as noted on the Instructions	Page.
I understand that I am providing "written instructions" under the Fair Credit Re on an ongoing basis as needed for the duration of my participation in programs profile or other information from the vendor through e-income verification whi qualifications for programs administered by PAP. I understand that I must affir process. I promise that any information, including financial and insurance infor provide additional documentation and that additional eligibility requirements	administered by Novo Nordisk PAP, to obtai ch will include a soft credit check, solely for t natively agree to these terms in order to pro mation that I provide is complete and true	in information from my credit the purpose of determining financial proceed in this financial screening
If you do not consent to an electronic income verification, please com	plete the information below and provid	e proof of income.
Total Household Annual Income \$		
# of people living in your household* (include yourself, spouse/partner, all adults)	# of dependents (under 18 years of ag	је) *
Patient Medicare Prescription Drug Coverage (Part I)) Enrollee Consent (if applica	ible)
I (or my parent/guardian/legal representative) agree that if I am (or the patient is may give my (or the patient's) Personal Information to the Centers for Medicare & enrollment status and let CMS and my (or the patient's) Medicare Part D plan kno understand that upon approval, I (or the patient) will receive up to a 120-day sup year. I (or my parent/guardian/legal representative) agree that I (or the patient): Medicare Part D prescription plan while receiving them from PAP; (ii) am not eligi program or third-party insurer; and (iii) and will not apply any PAP medication(s)	k Medicaid Services ("CMS") to confirm my (or w of this enrollment in PAP. Further, I (or my p oly of the medication(s) and/or device(s) from i) will not seek the requested Novo Nordisk m ble for reimbursement for any medication dis toward my (the patient's) True-Out-of-Pocket	the patient's) Medicare Part D oarent/guardian/legal representative) PAP through the end of this calendar nedication(s) from my (or the patient's) spensed by PAP from any government
Signature required ONLY if patient is a Medicare Part D enrollee M	iember Number/1D#*:	CICULATI
Patient or Parent/Guardian/Legal Representative Signature:		SIGNATU REQUIRE

PAP Application	Enrollment Year:
------------------------	------------------

Date:

Fiasp[®], FlexPen[®], FlexTouch[®], NovoFine[®], NovoIin[®], NovoLog[®], NovoPen Echo[®], PenFill[®], Tresiba[®], and Zegalogue[®] are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2023 Novo Nordisk All rights reserved. NNIMN_04_NOV2023 2

Novo Nordisk Minnesota State Insulin Affordability Program



SIGNATURE

REQUIRED

PATIENT SECTION (continued)

Asterisks indicate required field. Do not leave blank.

Date*:

Phone:

Patient Information

Patient First Name*:	Last Name*:	Patient DOB*:

HIPAA Authorization

By signing below, I (or my parent/guardian/legal representative) hereby give permission for my (or the patient's) health care providers, pharmacies, service providers and their contractors, health plans, and health insurer(s) and their contractors, to disclose any and all necessary information, including, but not limited to, my (or the patient's) income, prescription coverage, medical prescriptions, medical condition, financial documents, and health records ("Personal Information") to the Novo Nordisk's Patient Assistance Program (collectively, "PAP"). This Personal Information aids PAP in medical condition, financial documents, and health records ("Personal Information") to the Novo Nordisk's Patient Assistance Program (collectively, "PAP"). This Personal Information aids PAP in administering PAP by: (i) processing this Application; (ii) verifying my information") to the Novo Nordisk's Patient Assistance Program (collectively, "PAP"). This Personal Information aids PAP in administering PAP by: (i) processing this Application; (ii) verifying my information") to the Novo Nordisk's Patient Assistance Program (collectively, "PAP"). This Personal Information aids PAP in administering PAP by: (i) processing this Application; (ii) verifying my information") to the Novo Nordisk's Patient Assistance Program (collectively, "PAP"). This Personal Information to health Care Providers, Insurer(s), caregivers, Novo Nordisk, its affiliates, service providers, and agents (collectively "Novo Nordisk"), for the purposes described above. I (or my parent/guardian/legal representative) understand and acknowledge that while PAP, Novo Nordisk, and any authorized contractors acting on their behalf will make every effort to keep Personal Information private, once Personal Information is disclosed it may no longer be protected by federal privacy and security laws or applicable state laws. Specifically, I (or my parent/guardian/legal representative) acknowledge that once disclosed, Personal Information may be legally re-disclosed by authorized recipients unless otherwise prohibited by law. I (or my parent/guardian/legal representative) and that this authorization may be refused. I (or my parent/guardian/legal representative) may also revoke (withdraw) this authorization at any time in the future by calling 1-866-310-7549 or writing to Novo Nordisk, Inc. PO Box 370, Somerville, NJ 08876. Such refusal or future revocation will not affect my (or the patient's) commencement or continuation of treatment by healthcare providers, harmacies, services administered by PAP. If I (or my parent/guardian/legal representative) revoke thi By signing below, I acknowledge that I have read and agree to the Patient Authorization above.

I am signing on behalf of the patient, and I hereby affirm that I have the legal right to do so, that I am the parent or legal guardian of the patient, or that I otherwise have valid power of attorney to act on behalf of the patient.

Relationship to patient:

Patient or Legal Representative Signature*:

Legal Representative:

Telephone Consumer Protection Act ("TCPA") Communication Consent

I (or my parent/guardian/legal representative) also agree to be contacted by PAP and others on its behalf by telephone calls made by or using an automated dialing system or pre-recorded messages at the number(s) provided in this Application, for all non-marketing purposes. I (or my parent/guardian/legal representative) understand that I (or my parent/guardian/legal representative) may be asked to provide my (or the patient's) zip code and date of birth during pre-recorded calls in order to verify my (or the patient's) identity and that this information will not be retained by PAP or its partners but is simply to verify identity. I (or my parent/guardian/legal representative) agree to notify PAP promptly if any of my numbers or addresses change in the future. I (or my parent/guardian/legal representative) agree to notify PAP promptly if any of my numbers or addresses change in the future. I (or my parent/guardian/ legal representative) understand that this consent is not required, or a condition of purchase and it can be revoked at any time. I (or my parent/guardian/legal representative) further understand that I (or my parent/guardian/legal representative) can review the full Novo Nordisk Privacy Policy at https://www.novonordisk-us.com/privacy-notice.html. By providing a phone number and signing below, I acknowledge that I have read and agree to the TCPA Communication Consent above.

Phone*:

Safety Information

If a safety concern is reported, I (or my parent/guardian/legal representative) give permission to share my personal information to Novo Nordisk, who may contact me with follow-up inquiries, and who may report my personal information to the health authorities to comply with applicable rules and regulations.

Program Authorization & Certification

I (or my parent/guardian/legal representative) hereby certify that I (or my parent/guardian/legal representative): (i) am over 18; (ii) am a United States citizen or legal resident; (iii) do not have the ability to pay for the medication(s) requested by my (or the patient's) health care provider on the attached prescription(s) and I meet the financial criteria detailed on this application to qualify for the program. I also certify that I am not enrolled in or eligible for any of the following: (i) Medicaid; (ii) Medicare Extra Help/Low Income Subsidy ("LIS"); (iii) federally funded insurance programs, with the exception of Medicare Part D; or (iv) receive prescription drug benefits throughout the U.S. Veterans Administration, other than Medicare Part D. Patients enrolled in Medicare Part D who satisfy the exception of Medicare Part D, by or (iii) receive prescription drug benefits throughout the U.S. Veterans Administration, other than Medicare Part D. Patients enrolled in Medicare Part D who satisfy the financial eligibility criteria qualify for the program, but once enrolled, must stay in the program through the end of the calendar year. I certify that (i) all information provided in this application is true and correct and that I (or my parent/guardian/legal representative) will verify any of the information provided to PAP upon request; (ii) will verify my (or the patient's) application status and receipt of the indicated medication(s) upon request by PAP; (iii) if approved to participate in PAP. I (or my parent/guardian/legal representative) will not seek reimbursement for the medication(s) requested from any government program or third-party insurer; and (iv) will comply with any insurance carrier disclosure requirements, including my participation in PAP; (v) I (or my parent/guardian/legal representative) authorize PAP to contact me (or my parent/guardian/legal representative) by mail, email, and telephone (in accordance with the TCPA Communication Consent above) at the number(s), email(s), and address(es) provided on this application so that PAP can provide me with access to the products which I am prescribed.

I (or my parent/guardian/legal representative) understand and agree: (i) my eligibility to participate in PAP is subject to Novo Nordisk's decision and that Novo Nordisk may modify or terminate PAP at any time; (ii) I may be required to provide proof of ineligibility for certain other prescription drug coverage programs in order to meet the eligibility requirements for PAP; and (iii) I am required to report any changes to my health insurance and prescription drug coverage to PAP. I (or my parent/guardian/legal representative) understands that the product received through the PAP is provided to me free of charge and that I have no obligation to purchase the product due to my participation in the PAP. I (or my parent/guardian/legal representative) also give permission to PAP to combine or aggregate any information collected about me with information PAP may collect from other sources for the purpose of providing or administering PAP. In completing this Application, I confirm the following is complete and accurate and that I have read and agree to the Patient Authorization.

I am signing on behalf of the patient, and I hereby affirm that I have the legal right to do so, that I am the parent or legal guardian of the patient, or that I otherwise have valid power of attorney to act on behalf of the patient.

Patient or Legal Representative Signature*:		Date*:	SIGNATURE
Legal Representative:	Relationship to patient:	Phone:	

Patient First Name*

Novo Nordisk Minnesota State Insulin Affordability Program



SIGNATURE

REQUIRED

Asterisks indicate required field. Do not leave blank.

Patient DOB*:

Date*:

PRESCRIBER SECTION

Known Drug Allergies*:	

Prescriber Information (All medication will be shipped to the prescriber. No PO Box permitted.)

Last Name*

First Name*:		Last Name*:		Designation*:		
Street Address*:						
Suite/Building/Floor#:						
City:			Stat	e:	Zip:	
Phone*:		State License Number#*:			State Where Licensed:	
Fax*:	Office Contact:		Office Email:			
NPI*:	Days Office is Clo	osed for Deliveries:				
By signing below Lacknowledge that I have read and agree to the Health Care Practitioner Declaration. Products are dispensed as						

written. (Handwritten/valid electronic signatures accepted; no photocopies, power or attorney, or stamped signatures allowed) Health Care Practitioner Declaration: "My signature certifies that I am a licensed health care practitioner eligible under state law to prescribe, receive, and dispense the requested medication(s) listed on the attached order, shipped from Novo Nordisk, and that I am not prohibited from participating in federally funded health care programs. If I am a Nurse Practitioner, Physician Assistant, Pharmacist, or PharmD, I certify that I am authorized and eligible in the state within which I am currently practicing to prescribe, receive, and dispense these products, and that I have my supervising Physician's approval to do so if required by law. Note: Prescribing practitioner information must match practitioner's signature. I also certify that the product(s) being prescribed are to treat diagnosis(es) consistent with indication(s) and dosing described in the product's prescribing information. I further certify that all information provided in the Licensed Health Care Practitioner Information section is correct. I agree that medication(s) provided to me by Novo Nordisk for the applicant named in the Applicant Information section will be provided by me to such eligible applicant for his or her own use without charge. I will not otherwise use any of such medications or prescribe, provide or dispense all or any portion thereof for the use of any other person. I consent that Novo Nordisk may, at its discretion and with adequate notice, perform an on-site audit/review solely related to Novo Nordisk Diabetes Patient Assistance Program (PAP) records related to the applicant named above on this application. I understand that I am not eligible to seek reimbursement for any medication dispensed by PAP, from any government program or third-party insurer and will not apply any Novo Nordisk medication, provided by PAP, towards the applicant's True-Out-Of-Pocket (TrOOP) costs. I also understand that eligibili

Practitioner's Signature*:

KX						
Product	Max Dose/ Day (units)	Sig/Directions (e.g., QD, BID)	Formula	ation		Quantity
Fiasp [®] (insulin aspart) injection 100 U/mL			Vial	FlexTouch®	Cartridge	
Tresiba® (insulin degludec) injection U-100			Vial	FlexTouch®		
Insulin Degludec Injection U-100 (UB)			Vial	FlexTouch®		
Tresiba [®] (insulin degludec) injection U-200			FlexTo	uch®		
Insulin Degludec Injection U-200 (UB)			FlexTo	uch®		
NovoLog [®] (insulin aspart) injection 100 U/mL			Vial	FlexPen®	Cartridge	
Insulin Aspart Injection 100 U/mL (UB)			Vial	FlexPen®	Cartridge	
NovoLog [®] Mix 70/30 (insulin aspart protamine and insulin aspart injectable suspension) 100 U/mL			Vial	FlexPen®		
Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 100 U/mL (UB)			Vial	FlexPen®		
Novolin [®] R (insulin human injection) 100 U/mL			Vial			
Novolin [®] N (isophane insulin human suspension) 100 U/mL			Vial			
Novolin [®] 70/30 (human insulin isophane suspension and human insulin injection) 100 U/mL			Vial			
NovoFine [®] 32G 6mm (100 needles/box)						
Zegalogue [®] (dasiglucagon) injection 0.6 mg/0.6 mL		Auto-injector 1 Prefilled Syring	•	Auto-injecto Prefilled Syri	•	
NovoPen Echo®			1 pen			
All orders will be filled with up to a 120-day supply upless otherwise indicated by the prescriber Prescribers please complete the application with may daily						v daily

All orders will be filled with up to a **120-day** supply unless otherwise indicated by the prescriber. Prescribers, please complete the application with max daily dose and sig accordingly.

FlexPen®/FlexTouch® come in 5 pen packages and are used with Novo Nordisk disposable needles. Needles will not be sent as part of the Program order if they are not requested.

UB=Unbranded Biologic. Unbranded Biologics of Novo Nordisk-branded analog insulins are available from Novo Nordisk Pharma, Inc. (NNPI)

Fiasp®, FlexPen®, FlexTouch®, NovoFine®, Novolin®, NovoLog®, NovoPen Echo®, PenFill®, Tresiba®, and Zegalogue® are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2023 Novo Nordisk All rights reserved. NNIMN_04_NOV2023 4